T790米
细胞凋亡
突变体
化学
表皮生长因子受体抑制剂
表皮生长因子受体
IC50型
激酶
计算生物学
体外
生物
生物化学
受体
基因
吉非替尼
作者
Ahmed A. Abdel Gaber,Marwa Sharaky,Ayman Abo Elmaaty,Mohamed M. Hammouda,Ahmed A.E. Mourad,Samy Y. Elkhawaga,Mahmoud Mohamed Mokhtar,Amr S. Abouzied,Mai A.E. Mourad,Ahmed A. Al‐Karmalawy
出处
期刊:Future Medicinal Chemistry
[Newlands Press Ltd]
日期:2023-10-01
卷期号:15 (19): 1773-1790
被引量:4
标识
DOI:10.4155/fmc-2023-0156
摘要
Aim: Our objective was to design and synthesize a new range of pyrazolopyrimidines while maintaining the key pharmacophoric features of EGFR tyrosine kinase inhibitors. Materials & methods: Percentage inhibition in 14 human cancer cell lines and IC50 values were recorded. Compounds 6c, 7e and 7f were examined against both wild and mutant (T790M) EGFR subtypes. Apoptosis markers, cell cycle arrest, apoptosis assay and molecular docking were performed. Results: Compounds 6c, 7e and 7f demonstrated superior inhibitory potentials against wild and mutant (T790M) EGFR subtypes. A molecular docking study showed that compounds 6c and 7e had the best fit. Conclusion: The designed candidates demonstrated superior inhibitory potential as promising EGFR-T790M inhibitors that agrees with the proposed rationale.
科研通智能强力驱动
Strongly Powered by AbleSci AI